Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
David I Scheer
AddedMar 31, 2024
UpdatedMay 31, 2026
David I Scheer

David I Scheer

Board Member, Axerion Therapeutics

Crunchbase

David I Scheer's Career

Axerion Therapeutics
Axerion Therapeutics

Branford, CT, US

Board Member· Board
ReNetX Bio
ReNetX Bio

New Haven, CT, US

Board Member· Board
Optherion
Optherion

New Haven, CT, US

Board Member· Board
Adela
Adela

Foster City, CA, US

Board Member· Board
Sopherion Therapeutics
Sopherion Therapeutics

East Brunswick, NJ, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

David I Scheer's Career

Axerion Therapeutics
Axerion Therapeutics
Angel$1.1M342009Branford, CT, US
Board Member· Board

Leadership at Axerion Therapeutics

Sylvia McBrinnSylvia McBrinnBoard Member
David WurzerDavid WurzerBoard Member

Similar to Axerion Therapeutics

Axonia MedicalAxonia MedicalKalamazoo, MI, USMedical Researchest. 2011Axonia MedicalKalamazoo, MI, US · est. 2011

Axonia Medical Inc. pioneers in biomedical research, developing technology for neural restoration using tissue-engineered grafts.

Seed · $5M6
Axsome TherapeuticsAxsome TherapeuticsNew York City, NY, USTherapeuticsest. 2012Axsome TherapeuticsNew York City, NY, US · est. 2012

American biopharmaceutical firm, Axsome Therapeutics, develops therapies for pain and neurological disorders globally.

Public · $432M383
ReNetX Bio
ReNetX Bio

New Haven, CT, US

Board Member· Board
Optherion
Optherion

New Haven, CT, US

Board Member· Board
Adela
Adela
Series A$108M682020Foster City, CA, US
Board Member· Board

Leadership at Adela

Scott BratmanScott BratmanCo-Founder
Maneesh JainManeesh JainBoard Member
Daniel De CarvalhoDaniel De CarvalhoCo-Founder
Lisa AldersonLisa AldersonCEO
Sopherion Therapeutics
Sopherion Therapeutics
$163M02001East Brunswick, NJ, US
Co-Founder

Leadership at Sopherion Therapeutics

Andrew FirlikAndrew FirlikCo-Founder
Dr Joyce TsangDr Joyce TsangBoard Member
Peter ErnsterPeter ErnsterBoard Member

Similar to Sopherion Therapeutics

Sutro BiopharmaSutro BiopharmaSouth San Francisco, CA, USCancer Therapeuticsest. 2003Sutro BiopharmaSouth San Francisco, CA, US · est. 2003

Sutro Biopharma, a California-based medical firm, develops and manufactures cancer therapy drugs.

Public · $561.6M278
SphynKx TherapeuticsSphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Seed · $50k30
BioNumerik PharmaceuticalsBioNumerik PharmaceuticalsSan Antonio, TX, USCancer Drugsest. 1992BioNumerik PharmaceuticalsSan Antonio, TX, US · est. 1992

San Antonio-based Bionumerik Pharmaceuticals designs drugs for cancer treatment and prevention of therapy side effects.

Series A · $63.3M55

People Similar to David I Scheer

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJaeHong ChoiJaeHong ChoiBoard Member · KakaoKim Beom-sooKim Beom-sooCo-Founder · KakaoGeoffrey SmithGeoffrey SmithFounder · Digitalis VenturesMichael WassermanMichael WassermanBoard Member · Orbus TherapeuticsJack W. LasersohnJack W. LasersohnBoard Member · Silk Road MedicalKeith MurphyKeith MurphyBoard Member · VivoSim LabsBob RosenthalBob RosenthalBoard Member · Bruker BioSpinCraig C TaylorCraig C TaylorCo-Founder · Alloy Ventures